| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | CFO & Chief Strategy Officer
2 companies
Mani Mohindru is Chief Executive Officer at CRDF, with reported holdings spanning 2 companies. Mani Mohindru's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $66K at current prices.
Mani Mohindru's largest disclosed position is in CRDF as Chief Executive Officer, worth about $51K. Net of sales, the CRDF filings show accumulation of 59,067 shares.
Mani Mohindru has 29 Form 4 filings on record from January 2016 to July 2026, across 4 companies: Chief Executive Officer at Cardiff Oncology (CRDF), 2021–2026; Director at CytomX Therapeutics (CTMX), 2020–2026; CFO & Chief Strategy Officer at Tvardi Therapeutics (TVRD), 2017–2019, and 1 more.
The 36 reported transactions were 19 option or other derivative awards, 7 open-market sales, 4 option exercises and 3 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $80K and 7 sales worth about $2.1M.
The largest open-market purchase was 34,364 shares of CRDF at an average $1.46 on July 14, 2026, about $50K.
The largest open-market sale was 37,431 shares of TVRD at an average $25.00 on July 15, 2019, about $936K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | CRDF Cardiff Oncology, Inc. | Chief Executive Officer | Buy | 34,364 | $1.46 | $49,999.62 | +139.1% | -20.6% | - | |
| Jun 18, 2026 | CRDF Cardiff Oncology, Inc. | Chief Executive Officer | Buy | 24,703 | $1.21 | $29,890.63 | New | +11.6% | - | |
| Dec 4, 2019 | TVRD Tvardi Therapeutics, Inc. | CFO & Chief Strategy Officer | Sell | 4,755 | $17.05 | $81,072.75 | -21.4% | - | - | |
| Jul 15, 2019 | TVRD Tvardi Therapeutics, Inc. | CFO & Chief Strategy Officer | Sale+OE | 37,431 | $25.00 | $935,775.00 | -73.0% | - | - | |
| May 29, 2019 | TVRD Tvardi Therapeutics, Inc. | CFO & Chief Strategy Officer | Sell | 2,496 | $21.39 | $53,389.44 | -15.3% | - | - | |
| Mar 13, 2019 | TVRD Tvardi Therapeutics, Inc. | CFO & Chief Strategy Officer | Sale+OE | 16,041 | $19.12 | $306,703.92 | -66.7% | - | - | |
| Dec 28, 2018 | TVRD Tvardi Therapeutics, Inc. | CFO & Chief Strategy Officer | Sell | 4,500 | $12.55 | $56,475.00 | -35.9% | - | - | |
| Nov 15, 2018 | TVRD Tvardi Therapeutics, Inc. | CFO & Chief Strategy Officer | Sale+OE | 16,042 | $18.50 | $296,777.00 | - | - | - | |
| Oct 17, 2018 | TVRD Tvardi Therapeutics, Inc. | CFO & Chief Strategy Officer | Sale+OE | 16,042 | $20.19 | $323,887.98 | - | - | - |